{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"371","upperLimit":"1100","value":"585"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"dispersionType":"Inter-Quartile Range","groups":[{"description":"AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)","id":"OG000","title":"AZD6244"}],"paramType":"MEDIAN","populationDescription":"Eligible and Treated Patients with at least one post-dose pharmacokinetic time point available","reportingStatus":"POSTED","timeFrame":"Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment","title":"Maximum Concentration (Cmax) for AZD6244, 100 mg Administered Orally Twice Daily.","type":"PRIMARY","unitOfMeasure":"ng/mL"}